Shares of Allurion Technologies (ALUR, Financials) surged 80.5% in after-hours trading on Thursday, closing at $6.68 as of 7:59 p.m. GMT-5.
The company's announcement of intentions for a clinical trial combining its Allurion Program with GLP-1 treatments preceded the strong increase in the shares.
The research aims to solve the problem of muscle mass loss, which has been noted in up to 40% of overall weight reduction among GLP-1 treated individuals. Allurion emphasized earlier studies demonstrating that their non-invasive gastric balloon and Virtual Care Suite software helps patients lose notable weight while either retaining or even building muscle mass.
In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of effect on lean mass.
Combining weight reduction with muscle preservation in the latest clinical research would help to build a more efficient method of GLP-1 medication, the business said. It seeks to establish this mix as a standard for treatment of obesity.
Along with a Virtual Care Suite that provide tools for healthcare professionals to monitor and modify treatments, the Allurion Program has a swallowable gastric balloon that calls for no surgical procedure. The suite is also available separately, allowing for adaptable use in patient treatment.
The business expressed hope about the possibility to reinvent the standard of care in obesity treatment, even if it has not revealed a precise schedule for the research.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。